SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
25-Jan-24 3:29 PM View: | Howarth Alex G. Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 4,803 | -- | -- | 34% 13.93K to 18.74K | |
25-Jan-24 3:24 PM View: | Sibold William John President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 12,250 | -- | -- | 25% 50.0K to 62.25K | |
25-Jan-24 3:24 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 3,639 | -- | -- | 25% 14.58K to 18.22K | |
25-Jan-24 5:54 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 5,786 | -- | -- | < 1% 1.11M to 1.11M | |
25-Jan-24 5:50 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 1,419 | -- | -- | 28% 5.12K to 6.54K | |
25-Jan-24 6:04 PM View: | Huntsman Carole Chief Commercial Officer | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 3,639 | -- | -- | 46% 7.83K to 11.47K | |
18-Jan-24 1:52 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 949 | $243.92 | $231,480.00 | (6%) 15.53K to 14.58K | |
18-Jan-24 1:46 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 1,546 | $243.92 | $377,100.00 | (< 1%) 1.11M to 1.11M | |
18-Jan-24 1:45 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 550 | $243.92 | $134,156.00 | (10%) 5.67K to 5.12K | |
18-Jan-24 1:39 PM View: | Howarth Alex G. Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 1,067 | $243.92 | $260,263.00 | (7%) 15.0K to 13.93K | |
18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 15-Dec-23 | Option Exercise | 2,000 | $87.92 | $175,840.00 | 35% 5.67K to 7.67K | |
18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 15-Dec-23 | Option Sale | 2,000 | $238.50 | $477,000.00 | (26%) 7.67K to 5.67K | |
18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Private Option Sale | 2,000 | $232.50 | $465,000.00 | (26%) 7.67K to 5.67K | |
14-Dec-23 6:10 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Purchase | 20,633 | $228.32 | $4,710,890.00 | < 1% 3.75M to 3.77M | |
18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Option Exercise | 2,000 | $87.92 | $175,840.00 | 35% 5.67K to 7.67K | (7%) |
14-Dec-23 6:10 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Purchase | 81,159 | $219.39 | $17,805,700.00 | 4% 2.06M to 2.14M | |
14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Option Exercise | 2,500 | $87.92 | $219,800.00 | 44% 5.67K to 8.17K | |
14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Option Sale | 2,500 | $225.40 | $563,500.00 | (31%) 8.17K to 5.67K | |
14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Option Exercise | 1,300 | $87.92 | $114,296.00 | 23% 5.67K to 6.97K | (7%) |
14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Private Option Sale | 1,300 | $217.85 | $283,200.00 | (19%) 6.97K to 5.67K | |
14-Dec-23 6:09 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Purchase | 34,578 | $218.31 | $7,548,620.00 | 2% 1.84M to 1.88M | |
11-Dec-23 7:25 PM View: | Craves Fred B Director | Synta Pharmaceuticals Corp. (MDGL) | 07-Dec-23 | Disposition (other) | 1,556,590 | -- | -- | (76%) 2.05M to 489.69K | |
06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 05-Dec-23 | Option Exercise | 1,000 | $87.09 | $87,090.00 | 6% 15.53K to 16.53K | |
06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 05-Dec-23 | Option Sale | 1,000 | $227.33 | $227,330.00 | (6%) 16.53K to 15.53K | |
06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 04-Dec-23 | Private Option Sale | 1,800 | $218.87 | $393,964.00 | (10%) 17.33K to 15.53K | |
06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 04-Dec-23 | Option Exercise | 1,800 | $81.16 | $146,090.00 | 12% 15.53K to 17.33K | < 1% |
01-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 30-Nov-23 | Option Exercise | 3,000 | $73.75 | $221,250.00 | 19% 15.53K to 18.53K | |
01-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 30-Nov-23 | Option Sale | 3,000 | $204.58 | $613,730.00 | (16%) 18.53K to 15.53K | |
01-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 29-Nov-23 | Option Exercise | 4,000 | $73.75 | $295,000.00 | 26% 15.53K to 19.53K | 11% |
01-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 29-Nov-23 | Private Option Sale | 4,000 | $199.19 | $796,750.00 | (20%) 19.53K to 15.53K | |
21-Nov-23 6:15 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 21-Nov-23 | Purchase | 64,350 | $188.48 | $12,128,300.00 | 4% 1.78M to 1.84M | |
21-Nov-23 6:14 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 20-Nov-23 | Purchase | 20,709 | $185.74 | $3,846,580.00 | 1% 1.76M to 1.78M | |
22-Nov-23 5:02 PM View: | Huntsman Carole Chief Commercial Officer | Synta Pharmaceuticals Corp. (MDGL) | 20-Nov-23 | Grant | 7,834 | -- | -- | 100% 0 to 7.83K | |
21-Nov-23 6:14 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 17-Nov-23 | Purchase | 46,370 | $174.70 | $8,100,700.00 | 3% 1.71M to 1.76M | |
15-Nov-23 5:13 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 15-Nov-23 | Purchase | 15,199 | $161.97 | $2,461,720.00 | < 1% 1.7M to 1.71M | |
15-Nov-23 5:13 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Nov-23 | Purchase | 34,188 | $156.42 | $5,347,840.00 | 2% 1.66M to 1.7M | |
15-Nov-23 5:12 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Nov-23 | Purchase | 37,660 | $154.00 | $5,799,650.00 | 2% 1.62M to 1.66M | |
15-Nov-23 5:12 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 13-Nov-23 | Purchase | 69,839 | $143.21 | $10,001,400.00 | 4% 1.55M to 1.62M | |
13-Sep-23 4:41 PM View: | Sibold William John President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Sep-23 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
20-Jun-23 4:10 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 15-Jun-23 | Grant | 9,584 | -- | -- | < 1% 1.55M to 1.55M | |
02-Mar-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 01-Mar-23 | Option Exercise | 5,000 | $87.92 | $439,600.00 | 88% 5.67K to 10.67K | |
02-Mar-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 01-Mar-23 | Option Sale | 5,000 | $274.42 | $1,372,080.00 | (47%) 10.67K to 5.67K | |
02-Mar-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 28-Feb-23 | Private Option Sale | 5,000 | $272.07 | $1,360,360.00 | (47%) 10.67K to 5.67K | |
02-Mar-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 28-Feb-23 | Option Exercise | 5,000 | $87.92 | $439,600.00 | 88% 5.67K to 10.67K | (7%) |
11-Dec-23 7:25 PM View: | Craves Fred B Director | Synta Pharmaceuticals Corp. (MDGL) | 30-Jan-23 | Gift | 3,557 | -- | -- | (< 1%) 2.05M to 2.05M | |
19-Jan-23 7:57 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 17-Jan-23 | Option Exercise | 22,489 | $103.02 | $2,316,840.00 | 247% 9.1K to 31.59K | |
19-Jan-23 7:57 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 17-Jan-23 | Planned Option Sale | 22,489 | $293.15 | $6,592,690.00 | (71%) 31.59K to 9.1K | |
18-Jan-23 8:00 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-23 | Grant | 15,001 | -- | -- | 2830% 0.53K to 15.53K | |
18-Jan-23 8:00 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-23 | Grant | 5,667 | -- | -- | 100% 0 to 5.67K | |
18-Jan-23 8:00 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-23 | Grant | 20,001 | -- | -- | 2% 1.09M to 1.11M |